The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone

Diabetes and Metabolism Journal

Volumn 36, Issue 5, 2012, Pages 371-378

  Song, Sun Ok ^a   Kim, Kwang Joon ^a   Lee, Byung Wan ^a   Kang, Eun Seok ^a   Cha, Bong Soo ^a   Lee, Hyun Chul ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Diabetes mellitus; Korea; Pioglitazone; Type 2; Urinary bladder neoplasms

Indexed keywords

EID: 84870268099     PISSN: 22336079     EISSN: 22336087     Source Type: Journal    
DOI: 10.4093/dmj.2012.36.5.371     Document Type: Article

References (17)

1. Yoshimura R, Matsuyama M, Segawa Y, Hase T, Mitsuhashi M, Tsuchida K, Wada S, Kawahito Y, Sano H, Nakatani T. Expressionof peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer2003;104:597-602.
2. Cohen SM. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci 2005;87:3227
3. Aoki T. Current status of carcinogenicity assessment of peroxisomeproliferator-activated receptor agonists by the US FDA and a mode-of-action approach to the carcinogenic potential. J Toxicol Patho 2007;20:197-202.
4. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug advrse event reporting. Diabetes Care 2011;34:1369-71.
5. Stephenson J. Diabetes drug may be associated with increase in risk of bladder cancer. JAMA 2011;306:143.
6. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, QuesenberryCP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL. Risk of bladder cancer among diabetic patients treated with pioglitazone:interim report of a longitudinal cohort study. Diabetes Care 2011;34:91622.
7. Suh S, Kim KW. Diabetes and cancer: is diabetes causally relatedto cancer? Diabetes Metab J 2011;35:193-8.
8. Ogunleye AA, Ogston SA, Morris AD, Evans JM. A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer 209;101:1199-201.
9. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactiveinvestigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspectivepioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
10. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive investigators. Safety and tolerability of pioglitazone in hgh-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009;32:187-202
11. MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR. Diabetes and risk of bladder cancer: evidence from a case-controlstudy in New England. Cancer 2011;117:1552-6.
12. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012;35:278-80.
13. National Cancer Center: Annual report of cancer statistics in Korea in 2008. Available from: http://ncc.re.kr/manage/manage03_033_view.jsp?bbsnum=209&hSelSearch=&hTxtKeyword=¤t_page=1&cd=null (updated 2010 Dec 28).
14. Ko SH, Kim SR, Kim DJ, Oh SJ, Lee HJ, Shim KH, Woo MH, Kim JY, Kim NH, Kim JT, Kim CH, Kim HJ, Jeong IK, Hong EK, Cho JH, Mok J Yoon KH; Committee of Clinical Practice Guidelines, Korean Diabetes Association. 2011 Clinical practiceguidelines for type 2 diabetes in Korea. Diabetes Metab J 2011;35:431-6.
15. Rhee SY, Woo JT. The prediabetic period: review of clinical aspects.Diabetes Metab J 2011;35:107-16.
16. Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, Lopez-Abente G, Tzonou A, Chang-Claude J, Bolm-Audorff U, Jock KH, Donato F, Serra C, Wahrendorf J, Hours M, T'Mannetje A, Kogevinas M, Boffetta P. Cigarette smoking and bladder cancer in men a pooled analysis of 11 case-controlstudies. Int J Cancer 2000;86:289-94.
17. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities o premature cancer deaths. CA Cancer J Clin 2011;61:212-36.